We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




TB Screening Recommended for High-Risk Healthcare Workers Only

By LabMedica International staff writers
Posted on 08 Aug 2017
Print article
Image: A chart showing the costs associated with TB screening of healthcare workers (Image courtesy of McGill University Health Centre).
Image: A chart showing the costs associated with TB screening of healthcare workers (Image courtesy of McGill University Health Centre).
Routine screening for and treatment of latent tuberculosis (TB) infection has traditionally been an important part of TB prevention in Canadian and US healthcare institutions, but recent data have called into question its cost effectiveness. A new study has found that the current strategy of annual screening of is ineffectively expensive, suggesting that a switch to screening only high-risk healthcare workers is needed.

“The background rate of TB in North American communities is much lower today than it was 25 years ago when there were epidemics of TB in cities across the United States. As such, the risk of healthcare workers being exposed and infected at work is also much lower,’’ said study corresponding author Prof. Dr. Kevin Schwartzman, of McGill University Health Centre (MUHC; Montreal, Canada), Research Institute of MUHC, and McGill International TB Centre, “Our results suggest the annual TB screening protocol should be changed to reflect more accurately the epidemiology of TB in North America and potentially in other high-income countries, such as those in Northern Europe.’’

The researchers used published data to simulate the experience of a cohort of 1,000 workers who received a baseline negative test after hiring – considering duties, tuberculosis exposure, testing and treatment. They compared the cost-effectiveness of 3 screening strategies: annual screening (for all workers with significant patient contact), targeted screening (regular screening of only the highest risk workers), and post-exposure screening (screening only after identified exposure). They considered two tests to diagnose TB infection: the tuberculin skin test (TST) and the newer QuantiFERON-TB-Gold In-Tube (QFT) test from Qiagen. The QFT test was found to be more expensive to use than the TST test, with limited or no additional benefits.

“We projected costs, morbidity, quality-adjusted survival and mortality over 20 years after hiring. One of the most striking findings was that the current annual screening strategy costs over $1.7 million to prevent one additional case of active TB in a healthcare worker, when compared to a more targeted screening strategy, which in turn costs around $400,000 more per additional case when compared to the post-exposure screening protocol,’’ said study first-author Guillaume Mullie, medical student at McGill University, “The costs of current practices are quite significant for the healthcare system, and reconsideration of this long-standing recommendation may be warranted.’’ Dr. Schwartzman added, “The more you test healthcare workers without true exposure, the more likely it is that when you do find a positive test it will be a false positive because the tests are never perfect.”

According to the researchers, healthcare workers should not be called back routinely every year for testing just because that is the protocol. Instead, only workers at a particularly high-risk (for example respiratory therapists performing bronchoscopies, or microbiology laboratory workers) should continue to be tested regularly regardless of stated exposure. Other workers should be evaluated only after exposure to a contagious patient.

“Resources currently allocated to routine TB testing for healthcare workers in North America could instead be used to increase access to prevention, treatment, and testing infrastructure and support in communities that are at higher risk of developing TB disease, such as homeless, foreign-born, and indigenous people,” said Dr. Schwartzman.

The study, by Mullie GA et al, was published May 17, 2017, in the journal BMC Medicine.

Related Links:
McGill University Health Centre
Research Institute of MUHC
McGill International TB Centre

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.